Fumarate Hydratase (FH) is a mitochondrial enzyme catalyzing the reversible hydration of fumarate to malate in the TCA cycle. Defects in FH are linked to hereditary leiomyomatosis and renal cell carcinoma (HLRCC), as well as fumaric aciduria. Antibodies targeting FH are primarily used in research to study its expression, subcellular localization, and pathological roles.
Subcellular Localization: FH antibodies confirm cytoplasmic and mitochondrial localization of the enzyme .
Pathological Relevance: Defects in FH lead to fumaric aciduria, characterized by encephalopathy and metabolic acidosis .
Cancer Research: Overexpression of FH is studied in HLRCC, where antibodies aid in diagnosing tumor-associated mutations .
Factor H (FH) is a complement regulator that binds C3b, preventing excessive complement activation. Autoantibodies against FH are implicated in atypical hemolytic uremic syndrome (aHUS), a disorder causing thrombocytopenia, hemolytic anemia, and renal failure.
Complement Regulation: FH stabilizes C3bBb convertase decay and recruits factor I for C3b cleavage .
Genetic Predisposition: Anti-FH antibodies are linked to CFHR1/CFHR3 deletions, though not all carriers develop aHUS .
Treatment Outcomes: Plasma exchange and immunosuppression reduce mortality and improve renal function in aHUS patients .
| Feature | Fumarate Hydratase (FH) Antibodies | Factor H (FH) Antibodies |
|---|---|---|
| Primary Use | Research (WB, IHC, IF) | Diagnostic/Clinical (aHUS) |
| Host/Conjugate | Rabbit/Goat/Mouse; Cy5/HRP/FITC | Human (autoantibodies) or engineered mAbs |
| Key Targets | Mitochondrial/cytoplasmic FH | C3b-binding domains of FH |
| Clinical Impact | Diagnostic for HLRCC, fumaric aciduria | Prognostic marker for aHUS severity |